Abstract | BACKGROUND: PATIENTS AND METHODS: From July 1995 to September 1996, 20 untreated patients with locally advanced non-small cell lung cancer were enrolled in the study. Radiation at a dose of 44 Gy was initially delivered in daily fractions of 2 Gy 5 days a week to the tumor and mediastinum, followed by a boost to the tumor (20 to 26 Gy according to patients tolerance). Concurrently with thoracic irradiation, patients were treated with chemotherapy consisting of cisplatin at the dose of 60 mg/m2/d for 1 day, etoposide at the dose of 60 mg/m2/d for 2 days, and 5-FU 500 mg/m2/d plus leucovorin 50 mg/d infusion for 48 hours. Cycles of chemotherapy were repeated every 3 weeks for a maximum of 3 cycles. RESULTS: Seventeen of 20 patients were assessable. The overall response rate was 70.6% (95% confidence interval = 49-92%). No complete response was achieved. The median response duration for all responding patients is not yet estimable, with a range of 3.5 to 15.5+ months. Eleven patients remain progression-free for 4 to 15 months. The median survival for the entire group is not estimable. The major toxicity was esophagitis. Other grade 3 or 4 toxicities were not frequently observed. CONCLUSION:
|
Authors | C T Yang, W C Chang, L H Chen, W M Leung, C H Lee, C C Liaw |
Journal | Changgeng yi xue za zhi
(Changgeng Yi Xue Za Zhi)
Vol. 20
Issue 3
Pg. 187-94
(Sep 1997)
China (Republic : 1949- ) |
PMID | 9397609
(Publication Type: Journal Article)
|
Chemical References |
- Etoposide
- Cisplatin
- Leucovorin
- Fluorouracil
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(mortality, therapy)
- Cisplatin
(administration & dosage, adverse effects)
- Combined Modality Therapy
- Etoposide
(administration & dosage, adverse effects)
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Leucovorin
(administration & dosage, adverse effects)
- Lung Neoplasms
(mortality, therapy)
- Male
- Middle Aged
- Patient Compliance
- Radiotherapy
(adverse effects)
|